The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Cell Metabolism

• Publication date

  2012-09-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cmet.2012.06.016PMID 22921416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Poly(ADP-ribose)polymerase-1 (PARP1) controls adipogenic gene expression and adipocyte function.

  2012influential reference
• ARTD1 deletion causes increased hepatic lipid accumulation in mice fed a high‐fat diet and impairs adipocyte function and differentiation

  2012influential reference
• Age Related Changes in NAD+ Metabolism Oxidative Stress and Sirt1 Activity in Wistar Rats

  2011cited by this paper
• The hypoxic preconditioning agent deferoxamine induces poly(ADP-ribose) polymerase-1-dependent inhibition of the mitochondrial respiratory chain

  2011cited by this paper
• PARP-2 regulates SIRT1 expression and whole-body energy expenditure.

  2011influential reference
• PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation.

  2011influential reference
• The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets.

  2010influential reference
• PARP1 deficiency exacerbates diet-induced obesity in mice.

  2010cited by this paper
• Inflammatory and age-related pathologies in mice with ectopic expression of human PARP-1.

  2010cited by this paper
• The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways.

  2010influential reference
• Poly(ADP-ribose) polymerase 1 participates in the phase entrainment of circadian clocks to feeding.

  2010cited by this paper
• Circadian Control of the NAD+ Salvage Pathway by CLOCK-SIRT1

  2009cited by this paper
• SIRT1 Promotes Cell Survival under Stress by Deacetylation-Dependent Deactivation of Poly(ADP-Ribose) Polymerase 1

  2009cited by this paper
• Regulation of FOXO1-mediated transcription and cell proliferation by PARP-1.

  2009cited by this paper
• Identification of poly‐ADP‐ribosylated mitochondrial proteins after traumatic brain injury

  2008cited by this paper
• Poly(ADP-ribose) polymerase-2 [corrected] controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the retinoid X receptor/peroxisome proliferator-activated receptor-gamma [corrected] heterodimer.

  2007cited by this paper
• PARP-2 controls adipocyte differentiation and adipose tissue function through the regulation of the activity of the RXR/PPARγ heterodimer

  2007cited by this paper
• Functional Localization of Two Poly(ADP-Ribose)-Degrading Enzymes to the Mitochondrial Matrix

  2007cited by this paper
• Peroxisome Proliferator-activated Receptor (PPAR)-2 Controls Adipocyte Differentiation and Adipose Tissue Function through the Regulation of the Activity of the Retinoid X Receptor/PPARγ Heterodimer*

  2007cited by this paper
• Tricarboxylic Acid Cycle Substrates Prevent PARP-Mediated Death of Neurons and Astrocytes

  2002cited by this paper
• Mice lacking the poly(ADP-ribose) polymerase gene are resistant to pancreatic beta-cell destruction and diabetes development induced by streptozocin

  1999cited by this paper
• Amelioration of Diabetes Mellitus in Partially Depancreatized Rats by Poly(ADP-ribose) Synthetase Inhibitors: Evidence of Islet B-Cell Regeneration

  1984cited by this paper

• Clinical application of PARP inhibitors and emerging strategies to overcome resistance: a pan-cancer perspective.

  2026cites this paper
• PAR-Driven Condensation Maintains Stalled Replication Fork Stability

  2026cites this paper
• The effect of obesity and aging on NAD+/Sirtuin metabolism transcription and DNA methylation in subcutaneous adipose tissue of monozygotic twin pairs discordant for BMI.

  2026cites this paper
• Adaptive regulation of glycerophospholipid metabolism.

  2026cites this paper
• Network of nicotinamide mononucleotide biosynthesis: substrate tracking, rate-limiting enzyme, and regulatory strategy

  2025cites this paper
• Phospholipid Biosynthesis: An Unforeseen Modulator of Nuclear Metabolism

  2025cites this paper
• Machine Learning Models for High-Throughput Screening of Obesogens Based on Pathway Network

  2025cites this paper
• Protective Effects of GalNac-Modified Red Blood Cell-Derived Extracellular Vesicles Against Liver Diseases

  2025cites this paper
• PARP1 deficiency induces aging-associated cardiac failure via activation of Akt signalling

  2025cites this paper
• Uridine 5’-monophosphate (UMP) synthesis connects nucleotide metabolism to programmed cell death in C. elegans

  2025cites this paper
• PARylation-mediated post-transcriptional modifications in cancer immunity and immunotherapy

  2025cites this paper
• Therapeutic Potential of ACMSD Inhibitors in NAD+ Deficient Diseases

  2025cites this paper
• Oxidative–Inflammatory Crosstalk and Multi-Target Natural Agents: Decoding Diabetic Vascular Complications

  2025cites this paper
• Gal‐1 promotes lung cancer cell survival by enhancing PARP1/H1.2 interaction to promote DNA repair upon DNA damage response

  2025cites this paper
• Is NAD+ a key factor in ovarian aging and dysfunction? Insights and uncertainties from current research.

  2025cites this paper
• NAD(H) and NADP(H) in plants and mammals

  2025cites this paper
• Unravelling the genetics and epigenetics of the ageing tumour microenvironment in cancer

  2025cites this paper
• Ferroptosis: iron release mechanisms in the bioenergetic process

  2025cites this paper
• Role of Macrophage PARP1 in the Regulation of Crosstalk between Adipose Immune Cells and Adipocytes during Diet-induced Obesity

  2025cites this paper
• Oxidative stress-induced proinflammatory secretion from retinal pigment epithelium disrupts NAD+ metabolism via CD38 on macrophages leading to immune microenvironment dysregulation.

  2025cites this paper
• Specific and shared biological functions of PARP2 – is PARP2 really a lil’ brother of PARP1?

  2024cites this paper
• Molecular mechanisms of aging and anti-aging strategies

  2024cites this paper
• Chitosan/siRNA nanoparticles targeting PARP-1 attenuate Neuroinflammation and apoptosis in hyperglycemia-induced oxidative stress in Neuro2a cells.

  2024cites this paper
• Poly(ADP-Ribose) Polymerases-Inhibitor Talazoparib Inhibits Muscle Atrophy and Fatty Infiltration in a Tendon Release Infraspinatus Sheep Model: A Pilot Study

  2024cites this paper
• Functional deterioration of vascular mitochondrial and glycolytic capacity in the aortic rings of aged mice

  2024cites this paper
• Rational Design of PARP1/c-Met Dual Inhibitors for Overcoming PARP1 Inhibitor Resistance Induced by c-Met Overexpression.

  2024cites this paper
• Discovery of Potent Isoindolinone Inhibitors that Target an Active Conformation of PARP1 Using DNA‐Encoded Libraries

  2024cites this paper
• Targeting DNA damage response in pancreatic ductal adenocarcinoma: A review of preclinical and clinical evidence.

  2024cites this paper
• NAD(P)H-quinone oxidoreductase 1 induces complicated effects on mitochondrial dysfunction and ferroptosis in an expression level-dependent manner.

  2024cites this paper
• siRNA targeting PARP-1 alleviates diabetic peripheral neuropathy in a streptozotocin-induced rat model

  2024cites this paper
• A Molecular Perspective and Role of NAD+ in Ovarian Aging

  2024cites this paper
• PAR level mediates the link between ROS and inflammatory response in patients with type 2 diabetes mellitus

  2024cites this paper
• Acute nicotinamide riboside supplementation increases human cerebral NAD+ levels in vivo

  2024cites this paper
• PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes

  2024cites this paper
• Potential Therapeutic Interventions Targeting NAD+ Metabolism for ALS

  2024cites this paper
• Oxidative stress and PARP activation in the lungs is an early event in COVID-19 pneumonia

  2024cites this paper
• Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.

  2024cites this paper
• Organelle Communication with the Nucleus.

  2024cites this paper
• Ferroptosis: mechanism, immunotherapy and role in ovarian cancer

  2024cites this paper
• Beyond monotherapy: An era ushering in combinations of PARP inhibitors with immune checkpoint inhibitors for solid tumors.

  2024cites this paper
• Biological Functions and Therapeutic Potential of NAD+ Metabolism in Gynecological Cancers

  2024cites this paper
• The Rate of NAD+ Breakdown Is Maintained Constant against Deletion or Overexpression of NAD+-Degrading Enzymes in Mammalian Cells.

  2024cites this paper
• NAD+ metabolism and therapeutic strategies in cardiovascular diseases

  2024cites this paper
• NAD+ Boosting Strategies.

  2024cites this paper
• Emerging roles of TFE3 in metabolic regulation

  2023cites this paper
• Fer and FerT: A New Regulatory Link between Sperm and Cancer Cells

  2023cites this paper
• NAD+ metabolism-based immunoregulation and therapeutic potential

  2023cites this paper
• An update on Poly(ADP-ribose) polymerase I - A brief review.

  2023cites this paper
• Metabolism and Receptor Mechanisms of Niacin Action

  2023cites this paper
• NAD+ Homeostasis and NAD+-Consuming Enzymes: Implications for Vascular Health

  2023cites this paper
• PARP2 poly(ADP-ribosyl)ates nuclear factor erythroid 2-related factor 2 (NRF2) affecting NRF2 subcellular localization

  2023cites this paper
• Nicotinamide Mononucleotide Alleviates Angiotensin II-Induced Human Aortic Smooth Muscle Cell Senescence in a Microphysiological Model

  2023cites this paper
• Impact of NAD+ metabolism on ovarian aging

  2023cites this paper
• The Central Role of the NAD+ Molecule in the Development of Aging and the Prevention of Chronic Age-Related Diseases: Strategies for NAD+ Modulation

  2023cites this paper
• Combination Treatment Strategies to Overcome PARP Inhibitor Resistance

  2023cites this paper
• Discovery of a First-in-Class CD38 Inhibitor for the Treatment of Mitochondrial Myopathy.

  2023cites this paper
• Anemonin ameliorates human diploid fibroblasts 2BS and IMR90 cell senescence by PARP1-NAD+-SIRT1 signaling pathway.

  2023cites this paper
• Combinatorial treatment with PARP and MAPK inhibitors overcomes phenotype switch-driven drug resistance in advanced melanoma.

  2023cites this paper
• How ligands regulate the binding of PARP1 with DNA: Deciphering the mechanism at the molecular level

  2023cites this paper
• A new wave of innovations within the DNA damage response

  2023cites this paper
• Liquid-liquid phase separation in DNA double-strand breaks repair

  2023cites this paper
• Increased SIRT3 combined with PARP inhibition rescues motor function of SBMA mice

  2023cites this paper
• Nicotinamide Adenine Dinucleotide (NAD+)-Dependent Signaling in Neurological Disorders

  2023cites this paper
• Human PARP1 substrates and regulators of its catalytic activity: An updated overview

  2023cites this paper
• Poly (ADP-ribose) Polymerase Inhibition in Advanced Urothelial Carcinoma.

  2023cites this paper
• A systems-approach to NAD+ restoration.

  2022cites this paper
• Methods of PARP-1 Determination and its Importance in Living Organisims.

  2022cites this paper
• Correlation of Poly (adenosine diphosphate[ADP]-ribose) Polymerase Expression and Prognosis in Ovarian Cancer: A Systematic Review and Meta-analysis.

  2022cites this paper
• Aldehyde dehydrogenase 2 and PARP1 interaction modulates hepatic HDL biogenesis by LXRα-mediated ABCA1 expression

  2022cites this paper
• Neuralized-like protein 4 (NEURL4) mediates ADP-ribosylation of mitochondrial proteins

  2022cites this paper
• SIRT1 activation and its effect on intercalated disc proteins as a way to reduce doxorubicin cardiotoxicity

  2022cites this paper
• The cross-talk between PARylation and SUMOylation in C/EBPβ at K134 site participates in pathological cardiac hypertrophy

  2022cites this paper
• Long‐Term Activation of Glucagon‐like peptide‐1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes

  2022cites this paper
• Neuroprotective Effects of PARP Inhibitors in Drosophila Models of Alzheimer’s Disease

  2022cites this paper
• Depletion of PARP10 inhibits the growth and metastatic potential of oral squamous cell carcinoma

  2022cites this paper
• Expression profile of key genes involved in DNA repair mechanisms in bovine cumulus cells cultured with bovine serum albumin or fetal calf serum.

  2022cites this paper
• NAD+ Kinase Enzymes Are Reversible, and NAD+ Product Inhibition Is Responsible for the Observed Irreversibility of the Human Enzyme.

  2022cites this paper
• Balancing NAD+ deficits with nicotinamide riboside: therapeutic possibilities and limitations

  2022cites this paper
• Nicotinamide adenine dinucleotide attenuates acetaminophen-induced acute liver injury via activation of PARP1, Sirt1, and Nrf2 in mice.

  2022cites this paper
• NAD+ Precursors: A Questionable Redundancy

  2022cites this paper
• Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.

  2022cites this paper
• Modification Effect of PARP4 and ERCC1 Gene Polymorphisms on the Relationship between Particulate Matter Exposure and Fasting Glucose Level

  2022cites this paper
• Boosting mitochondrial health to counteract neurodegeneration.

  2022cites this paper
• A Double-Edged Sword: The Two Faces of PARylation

  2022cites this paper
• A Cytological Atlas of the Human Liver Proteome from PROTEOMESKY-LIVERHu 2.0, a Publicly Available Database.

  2022cites this paper
• Harnessing NAD+ Metabolism as Therapy for Cardiometabolic Diseases

  2022influential citation
• Synthesis and biological evaluation of a tumor-selective degrader of PARP1.

  2022cites this paper
• NAD+ Metabolism and Interventions in Premature Renal Aging and Chronic Kidney Disease

  2022cites this paper
• Role of PGC-1α in the Mitochondrial NAD+ Pool in Metabolic Diseases

  2021cites this paper
• NAD+ and NAFLD – caution, causality and careful optimism

  2021influential citation
• Regulation of the redox metabolome and thiol proteome by hydrogen sulfide

  2021cites this paper
• PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer

  2021cites this paper
• Inborn disorders of the malate aspartate shuttle

  2021cites this paper
• Uncovering the Invisible: Mono-ADP-ribosylation Moved into the Spotlight

  2021cites this paper
• PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling

  2021cites this paper
• Impact of the Cellular Zinc Status on PARP-1 Activity and Genomic Stability in HeLa S3 Cells.

  2021cites this paper
• Mutant NMNAT1 leads to a retina-specific decrease of NAD+ accompanied by increased poly(ADP-ribose) in a mouse model of NMNAT1-associated retinal degeneration.

  2021cites this paper
• Determination of the relationship between class IV sirtuin genes and growth traits in Chinese black Tibetan sheep

  2021cites this paper
• PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

  2021cites this paper
• NAD+ Metabolism and Diseases with Motor Dysfunction

  2021cites this paper